Mass Cytometry in Hematologic Malignancies: Research Highlights and Potential Clinical Applications

Recent advances in global gene sequencing technologies and the effect they have had on disease diagnosis, therapy, and research have fueled interest in technologies capable of more broadly profiling not only genes but proteins, metabolites, cells, and almost any other component of biological systems...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	John M. Astle, Huiya Huang
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	mass cytometry cyTOF hematologic oncology acute myeloid leukemia myeloma Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/293f78d58d20472a95df93e819edd3b3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:293f78d58d20472a95df93e819edd3b3
record_format	dspace
spelling	oai:doaj.org-article:293f78d58d20472a95df93e819edd3b32021-11-08T13:35:10ZMass Cytometry in Hematologic Malignancies: Research Highlights and Potential Clinical Applications2234-943X10.3389/fonc.2021.704464https://doaj.org/article/293f78d58d20472a95df93e819edd3b32021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fonc.2021.704464/fullhttps://doaj.org/toc/2234-943XRecent advances in global gene sequencing technologies and the effect they have had on disease diagnosis, therapy, and research have fueled interest in technologies capable of more broadly profiling not only genes but proteins, metabolites, cells, and almost any other component of biological systems. Mass cytometry is one such technology, which enables simultaneous characterization of over 40 parameters per cell, significantly more than can be achieved by even the most state-of-the-art flow cytometers. This mini-review will focus on how mass cytometry has been utilized to help advance the field of neoplastic hematology. Common themes among published studies include better defining lineage sub-populations, improved characterization of tumor microenvironments, and profiling intracellular signaling across multiple pathways simultaneously in various cell types. Reviewed studies highlight potential applications for disease diagnosis, prognostication, response to therapy, measurable residual disease analysis, and identifying new therapies.John M. AstleHuiya HuangFrontiers Media S.A.articlemass cytometrycyTOFhematologiconcologyacute myeloid leukemiamyelomaNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENFrontiers in Oncology, Vol 11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	mass cytometry cyTOF hematologic oncology acute myeloid leukemia myeloma Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	mass cytometry cyTOF hematologic oncology acute myeloid leukemia myeloma Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 John M. Astle Huiya Huang Mass Cytometry in Hematologic Malignancies: Research Highlights and Potential Clinical Applications
description	Recent advances in global gene sequencing technologies and the effect they have had on disease diagnosis, therapy, and research have fueled interest in technologies capable of more broadly profiling not only genes but proteins, metabolites, cells, and almost any other component of biological systems. Mass cytometry is one such technology, which enables simultaneous characterization of over 40 parameters per cell, significantly more than can be achieved by even the most state-of-the-art flow cytometers. This mini-review will focus on how mass cytometry has been utilized to help advance the field of neoplastic hematology. Common themes among published studies include better defining lineage sub-populations, improved characterization of tumor microenvironments, and profiling intracellular signaling across multiple pathways simultaneously in various cell types. Reviewed studies highlight potential applications for disease diagnosis, prognostication, response to therapy, measurable residual disease analysis, and identifying new therapies.
format	article
author	John M. Astle Huiya Huang
author_facet	John M. Astle Huiya Huang
author_sort	John M. Astle
title	Mass Cytometry in Hematologic Malignancies: Research Highlights and Potential Clinical Applications
title_short	Mass Cytometry in Hematologic Malignancies: Research Highlights and Potential Clinical Applications
title_full	Mass Cytometry in Hematologic Malignancies: Research Highlights and Potential Clinical Applications
title_fullStr	Mass Cytometry in Hematologic Malignancies: Research Highlights and Potential Clinical Applications
title_full_unstemmed	Mass Cytometry in Hematologic Malignancies: Research Highlights and Potential Clinical Applications
title_sort	mass cytometry in hematologic malignancies: research highlights and potential clinical applications
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/293f78d58d20472a95df93e819edd3b3
work_keys_str_mv	AT johnmastle masscytometryinhematologicmalignanciesresearchhighlightsandpotentialclinicalapplications AT huiyahuang masscytometryinhematologicmalignanciesresearchhighlightsandpotentialclinicalapplications
_version_	1718442218212032512

Mass Cytometry in Hematologic Malignancies: Research Highlights and Potential Clinical Applications

Ejemplares similares